Reporting of adverse events in targeted therapy and immunotherapy trials is 'suboptimal'
A significant number of trials of targeted therapies and immunotherapies in recent years show suboptimal reporting of adverse events, particularly the reporting of recurrent or late toxicities and the duration of the adverse ...
Oct 5, 2016
0
0